We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

TriLink Enters into Distribution Agreement with TATAA Biocenter


Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "TriLink Enters into Distribution Agreement with TATAA Biocenter"

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
 
Scandinavian based TATAA develops and performs a broad spectrum of hands-on qPCR courses worldwide, in addition to providing tailor-made products for real-time PCR applications.

As an innovative approach to Hot Start PCR, TriLink’s CleanAmp™ Product Line is an ideal complement to TATAA’s product and service offerings. In developing CleanAmp™, TriLink applied its expertise in modified nucleic acid chemistry to resolve common PCR problems, such as primer dimer formation and mis-priming. This advancement in Hot Start technology employs two widely ignored components of the PCR reagent mix: the primers and the dNTPs. The latest addition to the CleanAmp™ Product Line will be new, improved CleanAmp™ dNTPs, which will be available in April 2011. The latest advancement in CleanAmp™ dNTP chemistry allows improved amplicon yield in endpoint PCR and earlier Cq values in fast cycling real-time PCR.

“TATAA has established itself as a thought leader in the field of real-time PCR, and we are excited about the opportunity to expose our CleanAmp™ technology to the international research community through its training courses. We are confident that TATAA and its clients will be pleased with the results they see using CleanAmp™ Products,” stated TriLink’s President and CEO, Richard Hogrefe.

“The CleanAmp™ hot-start technique developed at TriLink is so much more versatile and easy to implement compared to alternatives, and being supported by our application specialists, we expect it will become a most popular product,” says Mikael Kubista, founder and CEO of TATAA Biocenter.

Advertisement